| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030443771 |
| P356 | DOI | 10.1007/S10637-016-0407-Y |
| P932 | PMC publication ID | 5893501 |
| P698 | PubMed publication ID | 27917453 |
| P2093 | author name string | Andrew J Brenner | |
| Andreas G Bader | |||
| Susan Smith | |||
| David S Hong | |||
| Yoon-Koo Kang | |||
| Sinil Kim | |||
| Muhammad S Beg | |||
| Mitesh Borad | |||
| Jasgit Sachdev | |||
| Jay Stoudemire | |||
| P2860 | cites work | Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia | Q38929504 |
| Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer | Q38972523 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells | Q39917469 | ||
| Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation | Q39949251 | ||
| Epigenetic Modulators and the New Immunotherapies | Q42699499 | ||
| Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation | Q43251963 | ||
| A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic | Q50899420 | ||
| MicroRNA and cancer. | Q53137197 | ||
| Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. | Q53172958 | ||
| MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma | Q57247811 | ||
| miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions | Q95780206 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 | Q24617130 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects | Q26864048 | ||
| Oncomirs - microRNAs with a role in cancer | Q27860773 | ||
| MicroRNA signatures in human cancers | Q27860962 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| The miR-34 family in cancer and apoptosis | Q28245865 | ||
| In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation | Q28271063 | ||
| Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34 | Q28285980 | ||
| A microRNA component of the p53 tumour suppressor network | Q28305330 | ||
| In-depth analysis shows synergy between erlotinib and miR-34a | Q28539851 | ||
| MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells | Q33497932 | ||
| MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary | Q33508232 | ||
| The Promise of MicroRNA Replacement Therapy | Q34134295 | ||
| miR-34 - a microRNA replacement therapy is headed to the clinic | Q34640230 | ||
| MicroRNA-34a enhances T cell activation by targeting diacylglycerol kinase ζ. | Q35023511 | ||
| Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy | Q35039281 | ||
| Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice | Q35086711 | ||
| Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs | Q35189998 | ||
| Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer | Q35496606 | ||
| Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. | Q35678607 | ||
| Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses | Q36015063 | ||
| The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis | Q36111707 | ||
| PDL1 Regulation by p53 via miR-34 | Q36887608 | ||
| TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). | Q37181402 | ||
| A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors | Q37539213 | ||
| Developing therapeutic microRNAs for cancer | Q37543146 | ||
| Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates | Q37696858 | ||
| Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention | Q37905250 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 180-188 | |
| P577 | publication date | 2016-12-05 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors | |
| P478 | volume | 35 |
| Q58105685 | 6mer seed toxicity in tumor suppressive microRNAs |
| Q57169221 | A General Overview on Non-coding RNA-Based Diagnostic and Therapeutic Approaches for Liver Diseases |
| Q38613166 | A New Network-Based Strategy for Predicting the Potential miRNA-mRNA Interactions in Tumorigenesis |
| Q37737945 | Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. |
| Q48297890 | Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications. |
| Q64084947 | Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis |
| Q90096291 | Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics |
| Q47117322 | Alternative mechanisms of miR-34a regulation in cancer |
| Q92152825 | Anti-miRNA Oligonucleotide Therapy for Chondrosarcoma |
| Q55266977 | Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript. |
| Q90344518 | Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression |
| Q60961938 | BC200 RNA: An Emerging Therapeutic Target and Diagnostic Marker for Human Cancer |
| Q52618071 | Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. |
| Q90237622 | Biology and clinical application of regulatory RNAs in hepatocellular carcinoma |
| Q92702538 | Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona |
| Q91809247 | Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in Intercellular Communication: One Cell's Trash Is Another Cell's Treasure |
| Q65556503 | Clinical cancer nanomedicine |
| Q91013857 | Controversies around epithelial-mesenchymal plasticity in cancer metastasis |
| Q92366665 | Curcumin rescues breast cells from epithelial‑mesenchymal transition and invasion induced by anti‑miR‑34a |
| Q92340490 | Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application |
| Q64056999 | Current Progress on MicroRNA-Based Gene Delivery in the Treatment of Osteoporosis and Osteoporotic Fracture |
| Q92346833 | Current role of non-coding RNAs in the clinical setting |
| Q47767814 | Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. |
| Q92512057 | Diminished LINC00173 expression induced miR-182-5p accumulation promotes cell proliferation, migration and apoptosis inhibition via AGER/NF-κB pathway in non-small-cell lung cancer |
| Q92447657 | Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma |
| Q92914310 | Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot-Marie-Tooth disease |
| Q64279445 | Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies |
| Q98771219 | Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets |
| Q38673790 | EMT: Present and future in clinical oncology |
| Q89796479 | Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview |
| Q91362890 | Engineering, delivery, and biological validation of artificial microRNA clusters for gene therapy applications |
| Q92478215 | Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics |
| Q64056234 | Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin |
| Q57170401 | Epigenetic Approaches to the Treatment of Dental Pulp Inflammation and Repair: Opportunities and Obstacles |
| Q64083693 | Epigenetic Influences in the Obesity/Colorectal Cancer Axis: A Novel Theragnostic Avenue |
| Q91864017 | Epigenetic influences on genetically triggered thoracic aortic aneurysm |
| Q92407472 | Epigenetics of colorectal cancer: biomarker and therapeutic potential |
| Q89719708 | Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance |
| Q47145765 | Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. |
| Q54205015 | Expression of miR-34a in T-Cells Infected by Human T-Lymphotropic Virus 1. |
| Q64241705 | Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma |
| Q52597886 | Hiding in Plain Sight: Rediscovering the Importance of Noncoding RNA in Human Malignancy. |
| Q99625021 | Hsa_circRNA_102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis |
| Q52677215 | Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. |
| Q90255557 | Lamins in Lung Cancer: Biomarkers and Key Factors for Disease Progression through miR-9 Regulation? |
| Q62512401 | Layer-by-layer assembled gold nanoshells for the intracellular delivery of miR-34a |
| Q57453171 | Let-7 microRNA as a potential therapeutic target with implications for immunotherapy |
| Q64989553 | Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. |
| Q90437022 | Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers |
| Q64068693 | Maternal circulating miRNAs that predict infant FASD outcomes influence placental maturation |
| Q64053396 | MiR-107 function as a tumor suppressor gene in colorectal cancer by targeting transferrin receptor 1 |
| Q93354312 | MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion |
| Q90608338 | MiR-206 may suppress non-small lung cancer metastasis by targeting CORO1C |
| Q61814242 | MiR-34a and miR-34b/c have distinct effects on the suppression of lung adenocarcinomas |
| Q47224057 | MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines |
| Q58753107 | MiRNA Dysregulation in Childhood Hematological Cancer |
| Q57491234 | Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma |
| Q64953093 | MicroRNA Dysregulation in Cutaneous Squamous Cell Carcinoma. |
| Q64108079 | MicroRNA in Lung Cancer Metastasis |
| Q98726639 | MicroRNA sequences modulating inflammation and lipid accumulation in macrophage "foam" cells: Implications for atherosclerosis |
| Q58548157 | MicroRNA-34 family in breast cancer: from research to therapeutic potential |
| Q61800287 | MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer |
| Q64058106 | MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating , and Caspase-3 |
| Q92858992 | MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma |
| Q44463289 | MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers. |
| Q91666392 | MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways |
| Q39406392 | MicroRNA-Directed Neuronal Reprogramming as a Therapeutic Strategy for Neurological Diseases |
| Q90699667 | MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers |
| Q91726315 | MicroRNAs in Animal Models of HCC |
| Q64103541 | MicroRNAs in Brain Cancer: Look at the Forest, Not at the Tree |
| Q90461158 | MicroRNAs in Cancer Treatment-Induced Cardiotoxicity |
| Q92541923 | MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities |
| Q39333266 | MicroRNAs in gynecological cancers: Small molecules with big implications |
| Q92144036 | MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential |
| Q90429127 | MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside |
| Q57148008 | Modulation of intracellular calcium signaling by microRNA-34a-5p |
| Q57174061 | Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration |
| Q91723129 | Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo |
| Q47135875 | N-AC-l-Leu-PEI-mediated miR-34a delivery improves osteogenic differentiation under orthodontic force |
| Q90419302 | Nanobiomaterials Used in Cancer Therapy: An Up-To-Date Overview |
| Q98464929 | Nanomaterials for Autophagy-Related miRNA-34a Delivery in Cancer Treatment |
| Q89896720 | Nanoparticle-Based Delivery of Tumor Suppressor microRNA for Cancer Therapy |
| Q50091869 | Nanotechnology as a Delivery Tool for Precision Cancer Therapies |
| Q64252020 | Neuropilins Controlling Cancer Therapy Responsiveness |
| Q89980594 | Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application |
| Q89968291 | Noninvasive quantification of SIRT1 expression-activity and pharmacologic inhibition in a rat model of intracerebral glioma using 2-[18F]BzAHA PET/CT/MRI |
| Q92824998 | Novel Biomarkers for Personalized Cancer Immunotherapy |
| Q58591484 | Nucleic Acid-Based Therapeutics for Pulmonary Diseases |
| Q90050680 | PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition |
| Q59790599 | Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors |
| Q90836137 | Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours |
| Q94450925 | Potential of activated microglia as a source of dysregulated extracellular microRNAs contributing to neurodegeneration in amyotrophic lateral sclerosis |
| Q99417440 | RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges |
| Q47565462 | RNA interference-based therapy and its delivery systems |
| Q90309160 | RNA therapy: Are we using the right molecules? |
| Q92747927 | ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer |
| Q91949964 | Relations between approved platinum drugs and non-coding RNAs in mesothelioma |
| Q89879065 | Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia |
| Q58695698 | Role of miR-223 in the pathophysiology of liver diseases |
| Q90713822 | Role of miRNAs in immune responses and immunotherapy in cancer |
| Q115232754 | Role of noncoding RNAs in Dengue virushost interaction |
| Q64259767 | Roles of MicroRNA-34a in Epithelial to Mesenchymal Transition, Competing Endogenous RNA Sponging and Its Therapeutic Potential |
| Q90740776 | Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer |
| Q92571307 | SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma |
| Q89556034 | STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia |
| Q42687704 | Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. |
| Q52562510 | Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. |
| Q41552623 | Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression |
| Q47112089 | Small RNAs May Answer Big Questions in Mental Illness |
| Q64100893 | Synthetic Design of Asymmetric miRNA with an Engineered 3' Overhang to Improve Strand Selection |
| Q92258573 | Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis |
| Q52726764 | Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. |
| Q52579251 | Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment. |
| Q37628264 | Targeting MicroRNAs in Cancer Gene Therapy |
| Q41239908 | Targeting MicroRNAs in Prostate Cancer Radiotherapy |
| Q89639511 | Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer |
| Q47133472 | Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma |
| Q92152187 | Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes |
| Q50092033 | Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs: miR-19b-1 role. |
| Q48308048 | Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies |
| Q41921194 | The Clinical Application of MicroRNAs in Infectious Disease |
| Q90411487 | The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target |
| Q92730656 | The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer |
| Q90249624 | The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug |
| Q39175956 | The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling |
| Q92081475 | The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy |
| Q38683271 | The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas |
| Q64098894 | The Roles of MicroRNA in Lung Cancer |
| Q92211257 | The Tumor Suppressor, p53, Negatively Regulates Non-Canonical NF-κB Signaling through miRNAInduced Silencing of NF-κB-Inducing Kinase |
| Q104742158 | The emerging role of small non-coding RNA in renal cell carcinoma |
| Q61118457 | The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma |
| Q47117573 | The role of miRNA and lncRNA in gastric cancer |
| Q39398929 | The role of microRNAs in colorectal liver metastasis: Important participants and potential clinical significances |
| Q90482676 | The role of noncoding RNAs in epithelial cancer |
| Q96609193 | Therapeutic siRNA: state of the art |
| Q94564366 | Transcription and Translation Inhibitors in Cancer Treatment |
| Q64238313 | Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer |
| Q64097271 | Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity |
| Q97538366 | Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer |
| Q42323428 | Up-regulation of microRNA let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl |
| Q48263612 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. |
| Q64064669 | lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway |
| Q33591563 | miR-106b-5p promotes renal cell carcinoma aggressiveness and stem-cell-like phenotype by activating Wnt/β-catenin signalling |
| Q92042005 | miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer |
| Q92942834 | miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A |
| Q94518094 | miR-185-5p response to usnic acid suppresses proliferation and regulating apoptosis in breast cancer cell by targeting Bcl2 |
| Q89511641 | miR-20b and miR-451a Are Involved in Gastric Carcinogenesis through the PI3K/AKT/mTOR Signaling Pathway: Data from Gastric Cancer Patients, Cell Lines and Ins-Gas Mouse Model |
| Q91013801 | miR-22 suppresses DNA ligase III addiction in multiple myeloma |
| Q47139724 | miR-34a expression in human breast cancer is associated with drug resistance |
| Q99572127 | miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer |
| Q64227609 | miRNAs expression of oral squamous cell carcinoma patients: Validation of two putative biomarkers |
| Q39285150 | miRNAs: micro-managers of anticancer combination therapies. |
| Q47375547 | microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview |
Search more.